Pulmo Protect Kft.
- Address
- Ezred Street 7 2nd Building 4th Floor, 1044 Budapest, Hungary
Combination Triple Therapy in COPD
At Pulmo Protect Kft., researchers are exploring triple inhaled therapy for patients with Chronic Obstructive Pulmonary Disease, aiming to reduce severe cardiopulmonary events.
- Comparison with dual bronchodilator regimens
- Focus on severe disease stages
- Assessment of cardiovascular safety
The work supports improved treatment options for individuals with advanced COPD in Europe.
AZD6793 Small‑Molecule Study
A trial at the Budapest site evaluates the investigational drug AZD6793 in moderate to very severe COPD to lower the frequency of exacerbations.
- Placebo‑controlled design
- Targeting reduction of moderate or severe flare‑ups
- Potential new oral therapy
Results could expand therapeutic choices for patients struggling with frequent exacerbations.
Verekitug Efficacy Research
The center is testing verekitug as a novel approach to improve disease control in adults with Chronic Obstructive Pulmonary Disease.
- Evaluation of exacerbation rates
- Assessment of symptom relief
- Exploration of novel mechanism of action
Success may offer an additional oral option for managing COPD symptoms.
Depemokimab Biologic Investigation
Researchers are conducting a study of the biologic depemokimab in COPD patients with type 2 inflammation, seeking longer‑term disease modification.
- Extended treatment duration assessment
- Focus on inflammatory phenotype
- Potential to reduce exacerbation burden
This work aligns with efforts to personalize therapy for inflammatory‑driven COPD.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pulmo Protect Kft.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO). | AstraZeneca AB | Phase II | Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Budesonide | 1 | Unknown | 2024-07-04 | 2024-07-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.